CRDL:CC - Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
(NewsDirect)
Toronto, ON,October 13, 2013 ( PlatoData via500NewsWire) -- In the United States, heart disease accounts for asignificant number of deaths every year, with cardiovascular diseasebeing the primary concern. Factors like lifestyle choices andunforeseen circumstances contribute to its prevalence.
Myocarditis(inflammation of the heart muscle) and pericarditis (inflammation ofthe heart's lining) are two inflammatory heart conditionsprimarily linked to immunological reactions from viral infections andmRNA vaccines. Though considered rare, awareness of these conditionsis growing, especially among younger populations.
Recent research inScience Immunology highlighted an increase in cytokine productionleading to myocarditis in individuals after their second dose ofcertain mRNA vaccines. The rise in heart-related incidents among youngathletes in recent years is an area of growing concern. While adversereactions to vaccines have historical precedence, the link betweenmyocarditis and certain vaccines is an area of ongoing study.
The treatment landscapein the U.S. presents challenges. Available treatments can be costlyand are often determined based on the severity of the case. Manyinstances of heart inflammation, while initially mild, can escalate ifmisdiagnosed or undetected, leading to significantcomplications.
Cardiol Therapeutics, Inc. has been proactive in addressingthese concerns. The company has developed two formulations,CardiolRx™ and CRD-38, to address the challenges posed byinflammatory heart diseases. CardiolRx™ is believed to reduceinflammatory cell activation and the subsequent production ofinflammatory cytokines. Additionally, this formulation has thepotential to minimize scar tissue formation in the heart muscle.
A notable feature ofCardiol’s formulations is the use of cannabidiol as the primaryactive ingredient. Their research initiatives position them at theforefront of treatment development for myocarditis and other severeheart conditions.
Increased awareness around myocarditis due to potentialvaccine-related complications has accelerated research efforts in thisdomain. There's a noted lack of standardized treatment for acutemyocarditis, and companies like Cardiol Therapeutics are spearheadingefforts to fill this gap.
An NIH study on cannabidiol hinted at its potentialcardioprotective properties, especially in models of diabetes-inducedheart failure. In contrast to traditional anti-inflammatories likesteroids, which are known for their side effects, cannabidiol-basedformulations from Cardiol have exhibited promising safety profiles inpreliminary studies.
CRD-38, one of Cardiol’s formulations, shows potential inaddressing heart failure with preserved ejection fraction (HFpEF).This formulation has demonstrated promising results in decreasingdetrimental visceral fat, commonly associated with conditions likeobesity, diabetes, and hypertension, and prevalent in HFpEF patients.Given the increasing cases of HFpEF and its associated mortality rate,CRD-38's potential impact is significant.
With ongoing phase IItrials and interim data expected soon, the advancements from CardiolTherapeutics could pave the way for innovative treatments in hearthealth care. As inflammatory heart diseases continue to be achallenge, especially for the younger population, innovations fromcompanies like Cardiol Therapeutics are more critical than ever.
About CardiolTherapeutics.
Web: https://www.cardiolrx.com/
Cardiol Therapeutics,Inc. is a clinical-stage life sciences company focused on the researchand clinical of anti-inflammatory and anti-fibrotic therapies for thetreatment of heart disease. Its lead product candidate, CardiolRx, isa pharmaceutically manufactured oral cannabidiol formulation that isbeing clinically developed for use in heart diseases. The firm isconducting clinical studies to evaluate the efficacy and safety ofCardiolRx in diseases affecting the heart: a Phase II multi-national,randomized, double-blind, placebo-controlled trial (the""ARCHER"" trial) in acute myocarditis; and a Phase IImulti-center open-label pilot study in recurrent pericarditis. It isalso involved in developing a novel subcutaneously administered drugformulation of cannabidiol intended for use in heart failure. Thecompany was founded by David Elsley, Eldon Smith, and Anthony Boltonon January 19, 2017 and is headquartered in Oakville, Canada.
Forward-LookingStatements
This press release contains forward-looking statements thatinvolve known and unknown risks and uncertainties. The Company'sactual results may differ materially from those anticipated in itsforward-looking statements. Factors that may cause such differencesinclude the Company's ability to develop its proposed. The Companyundertakes no obligation to revise or update any forward-lookingstatements to reflect events or circumstances that may arise after thedate hereof.
This Press Release is created by PlatoAi
ContactDetails
PlatoData AI powered by AmplifiPR
Copyright (c) 2023 TheNewswire - All rights reserved.